Liver transplantation for metastatic wild-type gastrointestinal stromal tumor in the era of molecular targeted therapies: Report of a first case.
cancer/malignancy/neoplasia: metastatic disease
clinical research/practice
immunosuppressive regimens
liver disease: malignant
liver transplantation/hepatology
organ allocation
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
11
01
2019
revised:
27
03
2019
accepted:
28
03
2019
pubmed:
4
4
2019
medline:
5
9
2020
entrez:
4
4
2019
Statut:
ppublish
Résumé
The gastrointestinal stromal tumor (GIST) is a digestive neoplasm of mesenchymal lineage. The treatment strategy for receptor tyrosine kinase-mutated GISTs is well defined. Wild-type GISTs (WT-GISTs) respond unsatisfactorily to specific kinase inhibitors. Moreover, evidence shows that repeat surgery has limited benefit. We report the case of a young female patient who was diagnosed with liver metastatic WT-GIST, after initial radical resection and adjuvant therapy with molecular targeted drugs. Due to the disease progression, a two-stage surgery was performed, with the removal of extrahepatic lesions followed by a total hepatectomy. The patient is disease-free after 4 years from liver transplantation (LT), performed under everolimus-based immunosuppression. The treatment of WT-GISTs remains a significant challenge due to the frequent resistance to tyrosine kinase inhibitors (TKIs). Liver transplantation might represent an effective treatment option for such disease.
Identifiants
pubmed: 30943317
doi: 10.1111/ajt.15377
pii: S1600-6135(22)09278-4
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2939-2943Informations de copyright
© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.
Références
Wada R, Arai H, Kure S, et al. “Wild type” GIST: clinicopathological features and clinical practice. Pathol Int. 2016;66(8):431-437.
Weldon CB, Madenci AL, Boikos SA, et al. Surgical management of wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Pediatric and Wildtype GIST Clinic. J Clin Oncol. 2017;35:523-528.
EASL Clinical Practice Guidelines. Liver transplantation. J Hepatol. 2016;64(2):433-485.
Pichlmayr R, Weimann A, Oldhafer KJ, et al. Appraisal of transplantation for malignant tumors of the liver with special reference to early stage hepatocellular carcinoma. Eur J Surg Oncol. 1998;24(1):60-67.
Lerut J, Iesari S, Foguenne M, et al. Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression? Transl Gastroenterol Hepatol. 2017;2:80.
Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472-480.
Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329-1338.
Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26(33):5352-5359.
National Comprehensive Cancer Network. Soft Tissue Sarcoma (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed February 18, 2019.
Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70-83.
Agaimy A, Wunsch PH. Lymph node metastasis in gastrointestinal stromal tumors (GIST) occurs preferentially in young patients < or = 40 years: an overview based on our case material and the literature. Langenbecks Arch Surg. 2009;394(2):375-381.
Valadao M, de Mello EL, Lourenco L, et al. What is the prognostic significance of metastatic lymph nodes in GIST? Hepatogastroenterology. 2008;55(82-83):471-474.
Cameron S, Ramadori G, Fuzesi L, et al. Successful liver transplantation in two cases of metastatic gastrointestinal stromal tumors. Transplantation. 2005;80(2):283-284.
Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36(6):320-328.
Mazzaferro V, Sposito C, Coppa J, et al. The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors. Am J Transplant. 2016;16(10):2892-2902.
Dueland SA, Foss JM, Solheim M, Hagness M, Line PD. Survival following liver transplantation for liver-only colorectal metastases compared with hepatocellular carcinoma. Br J Surg. 2018;105(6):736-742.
Uemura T, Wada S, Kaido T, et al. How far can we lower graft-to-recipient weight ratio for living donor liver transplantation under modulation of portal venous pressure? Surgery. 2016;159(6):1623-1630.